Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GAIN: ETC vs EC-TX and Ibandronate vs Observation in Node-positive Primary Breast Cancer
NCT00196872Phase 3Completed
- Sponsor
- GBG Forschungs
- Start
- Jul 2004
- Primary completion
- Jun 2014
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of capecitabine, ibandronate in breast cancer, sponsored by GBG Forschungs. Started Jul 2004; status: completed.
02
Drugs
capecitabineibandronate
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00196872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00196872.